100 top cell and gene therapy companies to watch in 2023

[Image courtesy of ipopba/Adobe Stock]

The cell and gene therapy sector is poised to deliver a wave of new therapies that could potentially cure rare and common diseases. As many as 13 new cell or gene therapies could be approved for use in the U.S., Europe, or both by the end of 2023.

While manufacturing and regulatory challenges remain, the cell and gene therapy industry continues to offer significant therapeutic potential and commercial opportunities.

This year, we have beefed up our list of leading cell and gene therapy companies, doubling the number of organizations from 50 to 100.

In selecting the companies for this list, we weighed public companies’ degree of involvement in cell and gene therapy, including drug developers, equipment vendors and CDMOs specializing in the area. For private companies, we factored in their funding levels, pipeline and degree of history for the list.

B…

Read more
  • 0

Intellia and Kyverna announce CAR-T pact

Genome editing company Intellia Therapeutics (NSDQ:NTLA) and cell therapy firm Kyverna Therapeutics have entered into a licensing and collaboration agreement to develop an allogeneic CD19 chimeric antigen receptor (CAR) T-cell therapy for various B cell-mediated autoimmune diseases.

Under the terms of the agreement, Intellia (Cambridge, Massachusetts) will get an equity stake in Kyverna (Emeryville, California) and has made an additional investment in the company. In exchange, Kyverna will get exclusive rights to use Intellia’s platform to develop KYV-201, an investigational CD19 CAR-T cell therapy.

Under the deal, Intellia also can exercise an option to manage U.S. commercialization activities related to KYV-201 in partnership with Kyverna. In such an arrangement, Intellia would pay an opt-in fee and cover half of the development costs while sharing half of the future U.S. revenue related to the drug. Additionally, Intellia would also get royalties on net sale…

Read more
  • 0